Indoor Harvest (INQD) 10-Q 1 Dec 23 2023 Q3 Quarterly report Financial data

Cover

Cover	9 Months Ended
	Sep. 30, 2023 shares
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2023
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	000-55594
Entity Registrant Name	INDOOR HARVEST CORP
Entity Central Index Key	0001572565
Entity Tax Identification Number	45-5577364
Entity Incorporation, State or Country Code	TX
Entity Address, Address Line One	7401 W. Slaughter Lane #5078
Entity Address, City or Town	Austin
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	78739
City Area Code	512
Local Phone Number	309-1776
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding	2,693,190.084

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Current Assets:
Cash	$ 6,504	$ 226,231
Notes receivable, net		163,588
Prepaid expenses and other receivable	44,833	44,085
Total Current Assets	51,337	433,904
Prepayment for acquisitions - related party	145,000	145,000
Acquisition deposit	440,239
TOTAL ASSETS	636,576	578,904
Current Liabilities:
Accounts payable and accrued liabilities	527,116	233,378
Convertible notes payable, net of debt discount of $0	359,375
Total Current Liabilities	886,491	233,378
Total Liabilities	886,491	233,378
Commitments and contingencies
Stockholders’ Equity
Preferred stock: 15,000,000 authorized; $0.01 par value; Series A Convertible Preferred stock: 15,000,000 designated, 0 shares issued and outstanding
Common stock: 10,000,000,000 authorized; $0.001 par value; 2,831,670,853 and 2,693,190,084 shares issued and outstanding, respectively	2,831,671	2,693,190
Additional paid in capital	25,032,565	24,135,367
Shares to be issued	382,250	576,000
Accumulated deficit	(28,496,401)	(27,059,031)
Total Stockholders’ Equity	(249,915)	345,526
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 636,576	$ 578,904

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Convertible notes payable, net of debt discount	$ 0	$ 0
Preferred Stock, shares authorized	15,000,000	15,000,000
Preferred Stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	10,000,000,000	10,000,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares issued	2,831,670,853	2,693,190,084
Common stock, shares outstanding	2,831,670,853	2,693,190,084
Series A Convertible Preferred Stock [Member]
Preferred Stock, shares authorized	15,000,000	15,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Revenue
Operating Expenses
Professional fees	189,414	251,468	685,701	1,269,671
General and administrative	69,056	323,505	376,451	1,655,924
Total Operating Expenses	258,469	574,973	1,062,151	2,925,595
Loss from operations	(258,469)	(574,973)	(1,062,151)	(2,925,595)
Other Income (Expense)
Interest income		1,857	3,373	1,857
Amortization of OID	(52,083)		(312,500)
Interest Expense	(61,141)		(66,092)
Total other income (expenses)	(113,224)	1,857	(375,219)	1,857
Income (loss) before income taxes	(371,694)	(573,116)	(1,437,370)	(2,923,738)
Provision for income taxes
Net income (loss)	(371,694)	(573,116)	(1,437,370)	(2,923,738)
Comprehensive income (Loss)	$ (371,694)	$ (573,116)	$ (1,437,370)	$ (2,923,738)
Basic and diluted income (loss) per common share
Basic	$ 0	$ 0	$ 0	$ 0
Diluted	$ 0	$ 0	$ 0	$ 0
Weighted average number of common shares outstanding
Basic	2,831,670,853	2,685,608,144	2,805,584,209	2,636,228,346
Diluted	2,831,670,853	2,685,608,144	2,805,584,209	2,636,228,346

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Series A Convertible Preferred Stock [Member] Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Stock Payable [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2021		$ 2,575,910	$ 21,210,721		$ (23,695,434)	$ 91,197
Balance, shares at Dec. 31, 2021		2,575,909,930
Stock based compensation			975,496			975,496
Net loss					(1,066,261)	(1,066,261)
Common stock issued for cash and warrant		$ 12,500	62,500			75,000
Common stock issued for cash and warrant, shares		12,500,000
Balance at Mar. 31, 2022		$ 2,588,410	22,248,717		(24,761,695)	75,432
Balance, shares at Mar. 31, 2022		2,588,409,930
Balance at Dec. 31, 2021		$ 2,575,910	21,210,721		(23,695,434)	91,197
Balance, shares at Dec. 31, 2021		2,575,909,930
Net loss						(2,923,738)
Proceeds received shares to be issued						250,000
Balance at Sep. 30, 2022		$ 2,689,190	24,048,979	250,000	(26,619,173)	368,996
Balance, shares at Sep. 30, 2022		2,689,190,084
Balance at Mar. 31, 2022		$ 2,588,410	22,248,717		(24,761,695)	75,432
Balance, shares at Mar. 31, 2022		2,588,409,930
Stock based compensation			1,023,688			1,023,688
Net loss					(1,284,362)	(1,284,362)
Common stock issued for cash and warrant		$ 89,600	358,400			448,000
Common stock issued for cash and warrant, shares		89,600,000
Common stock issued for cash -adjusted offerring price related to quarter 1st.		$ 2,500	(2,500)
Common stock issued for cash -adjusted offerring price related to quarter 1st, shares		2,500,000
Common stock issued for services		$ 834	4,166			5,000
Common stock issued for services, shares		834,000
Balance at Jun. 30, 2022		$ 2,681,344	23,632,471		(26,046,057)	267,758
Balance, shares at Jun. 30, 2022		2,681,343,930
Stock based compensation			373,354			373,354
Net loss					(573,116)	(573,116)
Proceeds received shares to be issued				250,000		250,000
Common stock issued for cash and warrant		$ 7,846	43,154			51,000
Common stock issued for cash and warrant, shares		7,846,154
Balance at Sep. 30, 2022		$ 2,689,190	24,048,979	250,000	(26,619,173)	368,996
Balance, shares at Sep. 30, 2022		2,689,190,084
Balance at Dec. 31, 2022		$ 2,693,190	24,135,367	576,000	(27,059,031)	345,526
Balance, shares at Dec. 31, 2022		2,693,190,084
Common stock and warrants issued		$ 107,231	589,769	(576,000)		121,000
Common stock and warrants issued, shares		107,230,769
Stock based compensation			64,384			64,384
Net loss					(373,727)	(373,727)
Balance at Mar. 31, 2023		$ 2,800,421	24,789,520		(27,432,758)	157,183
Balance, shares at Mar. 31, 2023		2,800,420,853
Balance at Dec. 31, 2022		$ 2,693,190	24,135,367	576,000	(27,059,031)	345,526
Balance, shares at Dec. 31, 2022		2,693,190,084
Net loss						(1,437,370)
Proceeds received shares to be issued
Balance at Sep. 30, 2023		$ 2,831,671	25,032,565	382,250	(28,496,401)	(249,915)
Balance, shares at Sep. 30, 2023		2,831,670,853
Balance at Mar. 31, 2023		$ 2,800,421	24,789,520		(27,432,758)	157,183
Balance, shares at Mar. 31, 2023		2,800,420,853
Common stock and warrants issued		$ 31,250	218,750			250,000
Common stock and warrants issued, shares		31,250,000
Stock based compensation			16,196			16,196
Net loss					(691,949)	(691,949)
Proceeds received shares to be issued				176,000		176,000
Balance at Jun. 30, 2023		$ 2,831,671	25,024,466	176,000	(28,124,707)	(92,570)
Balance, shares at Jun. 30, 2023		2,831,670,853
Common stock and warrants issued
Stock based compensation			8,099			8,099
Net loss					(371,694)	(371,694)
Proceeds received shares to be issued				206,250		206,250
Balance at Sep. 30, 2023		$ 2,831,671	$ 25,032,565	$ 382,250	$ (28,496,401)	$ (249,915)
Balance, shares at Sep. 30, 2023		2,831,670,853

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
OPERATING ACTIVITIES
Net Loss	$ (1,437,370)	$ (2,923,738)
Adjustments to reconcile Net Income to Net Cash provided by operations
Accrued interest – notes receivable	1,503	(919)
Amortization debt discount - Notes Receivable	(4,876)
Amortization of debt discount – interest expense	127,540
Stock based compensation	88,679	2,377,538
Escrow account	(25,000)
Prepaid expenses and other receivable	20,624	(57,968)
Accounts payable and accrued expenses	275,573	4,009
Due to related party		(33,902)
Net cash provided by operating activities	(953,327)	(634,981)
INVESTING ACTIVITIES
Investment in short term notes		(100,000)
Prepayments for acquisition – related party		(130,000)
Net cash provided by investing activities	(269,650)	(230,000)
FINANCING ACTIVITIES
Proceeds from convertible notes	250,000
Proceeds from stock subscriptions for shares to be issued		250,000
Proceeds from issuance of common stock and warrants	753,250	574,000
Net Cash provided by financing activities	1,003,250	824,000
Net cash increase for period	(219,727)	(40,981)
Cash at beginning of period	226,231	232,850
Cash at end of period	6,504	191,869
Supplemental Cash Flow Information
Cash paid for interest
Cash paid for taxes
369 Hemp Inc [Member]
INVESTING ACTIVITIES
Payments made for acquisition	(215,150)
Meta biogenix USA LLC [Member]
INVESTING ACTIVITIES
Payments made for acquisition	$ (54,500)

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Nature of Operations and Organization Indoor Harvest Corp (the “Company” or “Indoor Harvest”) is a Texas corporation formed on November 23, 2011. Our principal executive office was located at 7401 W. Slaughter Lane #5078, Austin, Texas 78739, and such address is used in the interim. We are in the process of establishing new offices. On August 14, 2019, the Company established a wholly owned subsidiary, IHC Consulting, Inc. (“IHC”), in the State of New York of the United States of America. IHC Consulting will provide consulting and other services to the Company and others on a contracted basis. The Company incorporates development of proprietary technology, mergers, acquisitions, strategic partnerships, and joint ventures as part of a broad integration strategy. As a platform, Indoor Harvest Corp. cultivates synergistic partnerships within related industries, providing an opportunity to be part of a more significant play, sharing intellectual capital, technology, access to new capital markets, and liquidity for owners. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the requirements of Form 10-Q and Rule 8-03 of Regulation S-X of the U.S. Securities and Exchange Commission. Accordingly, they may not include all of the information and disclosures required by accounting principles generally accepted in the United States of America for complete financial statements. Interim results are not necessarily indicative of results for a full year. In the opinion of management, all adjustments considered necessary for a fair presentation of the financial position and the results of operations and cash flows for the interim periods have been included. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2022, as not all disclosures required by generally accepted accounting principles for annual financial statements may be presented. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include, but are not limited to, the estimate of percentage of completion on construction contracts in progress at each reporting period which we rely on as a primary basis of revenue recognition, estimated useful lives of equipment for purposes of depreciation and the valuation of common shares issued for services, equipment and the liquidation of liabilities. Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All significant inter-company accounts and transactions have been eliminated in consolidation. Cash and Cash Equivalents The Company considers all highly liquid instruments with a maturity of three months or less to be cash and cash equivalents. Acquisition deposit The acquisitions of Hemp369 and MetaBioGenix have not been consummated at this time but are still contemplated. There are no letters or documents suggesting that any of the parties linked thereto have abandoned the transactions and they will move forward and be completed in the near future. For this reason, all payments from the Company are currently classified as acquisition deposit until legal completion of the transactions. Hemp369 and MetaBioGenix has a total of $ 385,739 54,500 Stock Based Compensation The Company recognizes stock-based compensation in accordance with ASC 718, Stock Compensation. ASC 718 focuses on transactions in which an entity exchanges its equity instruments for goods or services, with a primary focus in which an entity obtains employee services in stock-based payment transactions. ASC 718 requires measurement of the cost of employee services received in exchange for an award of equity instruments based on the grant date fair value of the award (with limited exceptions). Recently Adopted Accounting Pronouncements In August 2020, the FASB issued ASU 2020-06, ASC Subtopic 470-20 “Debt—Debt with “Conversion and Other Options” and ASC subtopic 815-40 “Hedging—Contracts in Entity’s Own Equity”. The standard reduced the number of accounting models for convertible debt instruments and convertible preferred stock. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting; and, (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. The amendments in this update are effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted. The Company has adopted the ASU as of January 1, 2022, there were no material impacts to the financial statements. Reclassification Certain accounts from prior periods have been reclassified to conform to the current period presentation. Fair Value of Financial Instruments As defined in ASC 820 “Fair Value Measurements,” fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. The Company classifies fair value balances based on the observability of those inputs. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement). The following table summarizes fair value measurements by level at September 30, 2023 and December 31, 2022, measured at fair value on a recurring basis: SCHEDULE OF FAIR VALUE OF ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS September 30,2023 Level 1 Level 2 Level 3 Total Assets: Notes receivables, net - - - - December 31,2022 Level 1 Level 2 Level 3 Total Assets: Notes receivable, net - - $ 163,588 $ 163,588

GOING CONCERN

GOING CONCERN	9 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	NOTE 2 - GOING CONCERN The accompanying unaudited consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. The Company had minimal cash as of September 30, 2023, incurred losses from its operations and did not generate cash from its operation for the past two years and nine months ended September 30, 2023. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company’s continued existence is dependent upon management’s ability to develop profitable operations, continued contributions from the Company’s executive officers to finance its operations and the ability to obtain additional funding sources to explore potential strategic relationships and to provide capital and other resources for the further development and marketing of the Company’s products and business.

NOTES RECEIVABLE

NOTES RECEIVABLE	9 Months Ended
	Sep. 30, 2023
Receivables [Abstract]
NOTES RECEIVABLE	NOTE 3 – NOTES RECEIVABLE During the nine months ended September 30, 2023, the Company granted loans of $ 0 SCHEDULE OF SECURED PROMISSORY NOTES Issuance date Amount Maturity date Rate Original Issue Discount 2023 2022 7/27/2022 40,000 5/27/2023 0.08 8/10/2022 20,000 6/10/2023 0.08 9/15/2022 40,000 1/15/2023 0.08 11/1/2022 25,000 3/1/2023 0.08 11/8/2022 20,000 3/8/2023 0.08 12/8/2022 15,000 4/8/2023 0.08 1/5/2023 27,500 7/5/2023 0.08 1/20/2023 50,000 7/20/2023 0.08 2/28/2023 65,000 9/28/2023 0.08 The notes are secured by an interest in real property as set nine security agreements between the Company and borrower. During the nine months ended September 30, 2023, the Company recognized interest income of $ 3,373

ACCOUNTS PAYABLE AND ACCRUED LI

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES	9 Months Ended
	Sep. 30, 2023
Payables and Accruals [Abstract]
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES	NOTE 4 – ACCOUNTS PAYABLE AND ACCRUED LIABILITIES Accounts payable and accrued liabilities on September 2023 and December 31, 2022 are as follows: SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES September 30, December 31, 2023 2022 Accounts payable $ 439,586 $ 139,603 Credit card 6,801 7,877 Accrued expenses 64,062 82,715 Accrued management fee 16,667 3,183 Total Accounts Payable And Accrued Liabilities $ 527,116 $ 233,378

STOCKHOLDERS_ EQUITY

STOCKHOLDERS’ EQUITY	9 Months Ended
	Sep. 30, 2023
Equity [Abstract]
STOCKHOLDERS’ EQUITY	NOTE 5 - STOCKHOLDERS’ EQUITY Common stock On August 1, 2022, the Company initiated a private placement offering for the sale of up to 123,076,923 0.0065 0.013 800,000 153,846,154 1,000,000 200,000,000 1,300,000 0.013 During the three months ended March 31, 2022, the Company issued 12,500,000 0.006 75,000 2,500,000 0 2,831,670,853 2,693,190,084 Shares to be issued During the year ended December 31, 2022, in connection with the mentioned private placement offering on August 12, 2022, the Company received $ 576,000 382,250 88,615,385 559,557,692 Additional paid in capital Stock Options In Q2 2023, consultants were each granted the option to purchase shares of common stock; Ken Tapp 10 10 100 10 130 0.01 In Q3 2023, consultant Summer Schnog was granted the option to purchase 50 0.01 Valuation The Company utilizes the Black-Scholes model to value its stock options. The Company utilized the following assumptions: The following is a summary of stock option activity during the nine months ended September 30, 2023. SCHEDULE OF STOCK OPTION Options Outstanding Weighted Average Number of Weighted Average Remaining life Options Exercise Price (years) Outstanding, December 31, 2022 854,000,000 $ 0.012 8.56 Granted 180,000,000 0.012 7.32 Exercised - - - Forfeited/canceled - - - Outstanding, September 30, 2023 1,034,000,000 0.012 7.32 Exercisable options, September 30, 2023 1,034,000,000 $ 0.012 7.32 Warrants In Q3 2023, an investor warrant total of 166 0.03 Valuation The Company utilizes the Black-Scholes model to value its stock options. The Company utilized the following assumptions: The following is a summary of warrant activity during the nine months ended September 30, 2023. SCHEDULE OF WARRANTS ACTIVITY Warrants Outstanding Weighted Average Number of Weighted Average Remaining life Warrants Exercise Price (years) Outstanding, December 31, 2022 116,446,154 $ 0.01 4.38 Granted 599,557,692 0.01 5.00 Exercised - - Forfeited/canceled - - Outstanding, September, 2023 716,003,846 $ 0.007 4.58

NET INCOME (LOSS) PER COMMON SH

NET INCOME (LOSS) PER COMMON SHARE	9 Months Ended
	Sep. 30, 2023
Earnings Per Share [Abstract]
NET INCOME (LOSS) PER COMMON SHARE	NOTE 6 - NET INCOME (LOSS) PER COMMON SHARE Basic net income per common share is computed by dividing net income by the weighted average number of common shares outstanding during the periods. Diluted net income per common share is computed using the weighted average number of common and dilutive common equivalent shares outstanding during the periods. Common equivalent shares consist of convertible preferred stock and convertible notes that are computed using the if-converted method, and outstanding warrants that are computed using the treasury stock method. Antidilutive stock awards consist of stock options that would have been antidilutive in the application of the treasury stock method. Net loss per share of common stock requires presentation of basic earnings per share on the face of the statements of operations for all entities with complex capital structures and requires a reconciliation of the numerator and denominator of the basic earnings per share computation. In the accompanying financial statements, basic loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share is computed by dividing net income by the weighted average number of shares of common stock and potentially dilutive outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through contingent share arrangements, stock options and warrants unless the result would be antidilutive. The dilutive effect of warrants and stock options subject to vesting and other share-based payment awards is calculated using the “treasury stock method,” which assumes that the “proceeds” from the exercise of these instruments are used to purchase common shares at the average market price for the period. The dilutive effect of convertible securities is calculated using the “if-converted method.” Under the if-converted method, securities are assumed to be converted at the beginning of the period, and the resulting common shares are included in the denominator of the diluted calculation for the entire period being presented. SCHEDULE OF DILUTED SECURITIES 2023 2022 Nine Months Ended September 30, 2023 2022 Warrants $ 716,003,846 $ 112,446,154 Stock Options $ 1,034,000,000 $ 840,000,000 Diluted Securities $ 1,750,003,846 $ 950,446,154 SCHEDULE OF EARNINGS PER SHARE, BASIC AND DILUTED 2023 2022 2023 2022 Three Months Ended Nine Months Ended 2023 2022 2023 2022 Numerator: Net income (loss) $ (371,694 ) $ (573,116 ) $ (1,437,370 ) $ (2,923,738 ) (Gain) loss on change in fair value of derivatives - - - - Interest on convertible debt - - - - Net income (loss) - diluted $ (371,694 ) $ (573,116 ) $ (1,437,370 ) $ (2,923,738 ) Denominator: Weighted average common shares outstanding 2,831,670,853 2,685,608,144 2,805,584,209 2,636,228,346 Effect of dilutive shares - - - Diluted 2,831,670,853 2,685,608,144 2,805,584,209 2,636,228,346 Net income (loss) per common share: Basic $ (0.00 ) $ (0.00 ) $ (0.00 ) $ (0.00 ) Diluted $ (0.00 ) $ (0.00 ) $ (0.00 ) $ (0.00 ) For the three and nine months ended September 30, 2023, the convertible instruments are anti-dilutive and therefore, have been excluded from earnings (loss) per share.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Sep. 30, 2023
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 7- RELATED PARTY TRANSACTIONS On February 8, 2022, the Company entered an assets acquisition Letter of Intent (“LOI”) with an entity under common control with the Company. During the nine months ended September 30, 2023, in connection with the LOI, the Company paid advance of $ 145,000 During the nine months ended September 30, 2023 and 2022, the Company paid consulting fees of $ 246,000 307,000

ACQUISITION

ACQUISITION	9 Months Ended
	Sep. 30, 2023
Business Combination and Asset Acquisition [Abstract]
ACQUISITION	NOTE 8- ACQUISITION On April 28, 2023, The Company entered into a Membership Interest and Stock Purchase Agreement with an individual (Seller) to buy 100 Under the terms of the Agreement, the aggregate purchase price of $ 1,675,000 800,000 313,089 125,000,000 0.001 On April 30, 2023, Indoor Harvest Corp. (“Indoor Harvest”) entered into a Membership Interest and Stock Purchase Agreement with Metabiogenix USA, LLC, a Texas limited liability company (the “Company”), Metabiogenics, Ltd., S.A. de C.V. and other individual members of the Company, (each a “Seller” and collectively the “Sellers”), and Sellers owns all of the issued and outstanding membership interests (the “Membership Interests”) of the Company. The Agreement provides that, subject to the terms and conditions set forth therein, Indoor Harvest will acquire a sixty percent ( 60 Under the terms of the Agreement, the aggregate purchase price of $ 2,500,000 400,000 100,000 50,000 250,000 300,000,000 0.001 150,000,000 Metabiogenix USA, LLC, is the officially licensed distributor of Metabiox® across the Western Hemisphere (North, South, and Central America), and Spain. Metabiox® was developed by the Japanese Medical Institute and is produced in Japan. On April 12,2023, the Company’s board of directors approved to issue a convertible note of $ 312,500 20 6 31,250,000 31,250,000 0.01 180,500 The acquisition process of Hemp369 and MetaBioGenix is taking longer than anticipated due to initial investors’ liquidity change. The delay could result in the loss of valuable employees, the disruption of ongoing productions, and business relationships, any of which could adversely affect our ability to achieve the anticipated benefits of the acquisition. In order to sustain the paused acquisition, the Company has continued to make payment to Hemp369 during the third quarter of 2023, in the sum of $ 44,229 44,229 385,739 54,500

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 9- SUBSEQUENT EVENTS Management has evaluated subsequent events through the date these financial statements were available to be issued. Based on our evaluation no material events have occurred that require disclosure.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Nature of Operations and Organization	Nature of Operations and Organization Indoor Harvest Corp (the “Company” or “Indoor Harvest”) is a Texas corporation formed on November 23, 2011. Our principal executive office was located at 7401 W. Slaughter Lane #5078, Austin, Texas 78739, and such address is used in the interim. We are in the process of establishing new offices. On August 14, 2019, the Company established a wholly owned subsidiary, IHC Consulting, Inc. (“IHC”), in the State of New York of the United States of America. IHC Consulting will provide consulting and other services to the Company and others on a contracted basis. The Company incorporates development of proprietary technology, mergers, acquisitions, strategic partnerships, and joint ventures as part of a broad integration strategy. As a platform, Indoor Harvest Corp. cultivates synergistic partnerships within related industries, providing an opportunity to be part of a more significant play, sharing intellectual capital, technology, access to new capital markets, and liquidity for owners.
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the requirements of Form 10-Q and Rule 8-03 of Regulation S-X of the U.S. Securities and Exchange Commission. Accordingly, they may not include all of the information and disclosures required by accounting principles generally accepted in the United States of America for complete financial statements. Interim results are not necessarily indicative of results for a full year. In the opinion of management, all adjustments considered necessary for a fair presentation of the financial position and the results of operations and cash flows for the interim periods have been included. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2022, as not all disclosures required by generally accepted accounting principles for annual financial statements may be presented.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include, but are not limited to, the estimate of percentage of completion on construction contracts in progress at each reporting period which we rely on as a primary basis of revenue recognition, estimated useful lives of equipment for purposes of depreciation and the valuation of common shares issued for services, equipment and the liquidation of liabilities.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All significant inter-company accounts and transactions have been eliminated in consolidation.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid instruments with a maturity of three months or less to be cash and cash equivalents.
Acquisition deposit	Acquisition deposit The acquisitions of Hemp369 and MetaBioGenix have not been consummated at this time but are still contemplated. There are no letters or documents suggesting that any of the parties linked thereto have abandoned the transactions and they will move forward and be completed in the near future. For this reason, all payments from the Company are currently classified as acquisition deposit until legal completion of the transactions. Hemp369 and MetaBioGenix has a total of $ 385,739 54,500
Stock Based Compensation	Stock Based Compensation The Company recognizes stock-based compensation in accordance with ASC 718, Stock Compensation. ASC 718 focuses on transactions in which an entity exchanges its equity instruments for goods or services, with a primary focus in which an entity obtains employee services in stock-based payment transactions. ASC 718 requires measurement of the cost of employee services received in exchange for an award of equity instruments based on the grant date fair value of the award (with limited exceptions).
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In August 2020, the FASB issued ASU 2020-06, ASC Subtopic 470-20 “Debt—Debt with “Conversion and Other Options” and ASC subtopic 815-40 “Hedging—Contracts in Entity’s Own Equity”. The standard reduced the number of accounting models for convertible debt instruments and convertible preferred stock. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting; and, (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. The amendments in this update are effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted. The Company has adopted the ASU as of January 1, 2022, there were no material impacts to the financial statements.
Reclassification	Reclassification Certain accounts from prior periods have been reclassified to conform to the current period presentation.
Fair Value of Financial Instruments	Fair Value of Financial Instruments As defined in ASC 820 “Fair Value Measurements,” fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. The Company classifies fair value balances based on the observability of those inputs. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement). The following table summarizes fair value measurements by level at September 30, 2023 and December 31, 2022, measured at fair value on a recurring basis: SCHEDULE OF FAIR VALUE OF ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS September 30,2023 Level 1 Level 2 Level 3 Total Assets: Notes receivables, net - - - - December 31,2022 Level 1 Level 2 Level 3 Total Assets: Notes receivable, net - - $ 163,588 $ 163,588

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
SCHEDULE OF FAIR VALUE OF ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS	The following table summarizes fair value measurements by level at September 30, 2023 and December 31, 2022, measured at fair value on a recurring basis: SCHEDULE OF FAIR VALUE OF ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS September 30,2023 Level 1 Level 2 Level 3 Total Assets: Notes receivables, net - - - - December 31,2022 Level 1 Level 2 Level 3 Total Assets: Notes receivable, net - - $ 163,588 $ 163,588

NOTES RECEIVABLE (Tables)

NOTES RECEIVABLE (Tables)	9 Months Ended
	Sep. 30, 2023
Receivables [Abstract]
SCHEDULE OF SECURED PROMISSORY NOTES	During the nine months ended September 30, 2023, the Company granted loans of $ 0 SCHEDULE OF SECURED PROMISSORY NOTES Issuance date Amount Maturity date Rate Original Issue Discount 2023 2022 7/27/2022 40,000 5/27/2023 0.08 8/10/2022 20,000 6/10/2023 0.08 9/15/2022 40,000 1/15/2023 0.08 11/1/2022 25,000 3/1/2023 0.08 11/8/2022 20,000 3/8/2023 0.08 12/8/2022 15,000 4/8/2023 0.08 1/5/2023 27,500 7/5/2023 0.08 1/20/2023 50,000 7/20/2023 0.08 2/28/2023 65,000 9/28/2023 0.08

ACCOUNTS PAYABLE AND ACCRUED _2

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)	9 Months Ended
	Sep. 30, 2023
Payables and Accruals [Abstract]
SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES	Accounts payable and accrued liabilities on September 2023 and December 31, 2022 are as follows: SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES September 30, December 31, 2023 2022 Accounts payable $ 439,586 $ 139,603 Credit card 6,801 7,877 Accrued expenses 64,062 82,715 Accrued management fee 16,667 3,183 Total Accounts Payable And Accrued Liabilities $ 527,116 $ 233,378

STOCKHOLDERS_ EQUITY (Tables)

STOCKHOLDERS’ EQUITY (Tables)	9 Months Ended
	Sep. 30, 2023
Equity [Abstract]
SCHEDULE OF STOCK OPTION	The following is a summary of stock option activity during the nine months ended September 30, 2023. SCHEDULE OF STOCK OPTION Options Outstanding Weighted Average Number of Weighted Average Remaining life Options Exercise Price (years) Outstanding, December 31, 2022 854,000,000 $ 0.012 8.56 Granted 180,000,000 0.012 7.32 Exercised - - - Forfeited/canceled - - - Outstanding, September 30, 2023 1,034,000,000 0.012 7.32 Exercisable options, September 30, 2023 1,034,000,000 $ 0.012 7.32
SCHEDULE OF WARRANTS ACTIVITY	The following is a summary of warrant activity during the nine months ended September 30, 2023. SCHEDULE OF WARRANTS ACTIVITY Warrants Outstanding Weighted Average Number of Weighted Average Remaining life Warrants Exercise Price (years) Outstanding, December 31, 2022 116,446,154 $ 0.01 4.38 Granted 599,557,692 0.01 5.00 Exercised - - Forfeited/canceled - - Outstanding, September, 2023 716,003,846 $ 0.007 4.58

NET INCOME (LOSS) PER COMMON _2

NET INCOME (LOSS) PER COMMON SHARE (Tables)	9 Months Ended
	Sep. 30, 2023
Earnings Per Share [Abstract]
SCHEDULE OF DILUTED SECURITIES	SCHEDULE OF DILUTED SECURITIES 2023 2022 Nine Months Ended September 30, 2023 2022 Warrants $ 716,003,846 $ 112,446,154 Stock Options $ 1,034,000,000 $ 840,000,000 Diluted Securities $ 1,750,003,846 $ 950,446,154
SCHEDULE OF EARNINGS PER SHARE, BASIC AND DILUTED	SCHEDULE OF EARNINGS PER SHARE, BASIC AND DILUTED 2023 2022 2023 2022 Three Months Ended Nine Months Ended 2023 2022 2023 2022 Numerator: Net income (loss) $ (371,694 ) $ (573,116 ) $ (1,437,370 ) $ (2,923,738 ) (Gain) loss on change in fair value of derivatives - - - - Interest on convertible debt - - - - Net income (loss) - diluted $ (371,694 ) $ (573,116 ) $ (1,437,370 ) $ (2,923,738 ) Denominator: Weighted average common shares outstanding 2,831,670,853 2,685,608,144 2,805,584,209 2,636,228,346 Effect of dilutive shares - - - Diluted 2,831,670,853 2,685,608,144 2,805,584,209 2,636,228,346 Net income (loss) per common share: Basic $ (0.00 ) $ (0.00 ) $ (0.00 ) $ (0.00 ) Diluted $ (0.00 ) $ (0.00 ) $ (0.00 ) $ (0.00 )

SCHEDULE OF FAIR VALUE OF ASSET

SCHEDULE OF FAIR VALUE OF ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Platform Operator, Crypto-Asset [Line Items]
Notes receivable, net		$ 163,588
Fair Value, Inputs, Level 1 [Member]
Platform Operator, Crypto-Asset [Line Items]
Notes receivable, net
Fair Value, Inputs, Level 2 [Member]
Platform Operator, Crypto-Asset [Line Items]
Notes receivable, net
Fair Value, Inputs, Level 3 [Member]
Platform Operator, Crypto-Asset [Line Items]
Notes receivable, net		$ 163,588

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Restructuring Cost and Reserve [Line Items]
Acquisition deposit	$ 440,239
369 Hemp Inc [Member]
Restructuring Cost and Reserve [Line Items]
Acquisition deposit	385,739
Meta biogenix USA LLC [Member]
Restructuring Cost and Reserve [Line Items]
Acquisition deposit	$ 54,500

SCHEDULE OF SECURED PROMISSORY

SCHEDULE OF SECURED PROMISSORY NOTES (Details)	9 Months Ended
	Sep. 30, 2023 USD ($)
Secured Promissory Note One [Member]
Receivables with Imputed Interest [Line Items]
Issuance date	Jul. 27, 2022
Principal amount	$ 40,000
Maturity date	May 27, 2023
Interest rate	0.08%
Secured Promissory Note Two [Member]
Receivables with Imputed Interest [Line Items]
Issuance date	Aug. 10, 2022
Principal amount	$ 20,000
Maturity date	Jun. 10, 2023
Interest rate	0.08%
Secured Promissory Note Three [Member]
Receivables with Imputed Interest [Line Items]
Issuance date	Sep. 15, 2022
Principal amount	$ 40,000
Maturity date	Jan. 15, 2023
Interest rate	0.08%
Secured Promissory Note Four [Member]
Receivables with Imputed Interest [Line Items]
Issuance date	Nov. 01, 2022
Principal amount	$ 25,000
Maturity date	Mar. 01, 2023
Interest rate	0.08%
Secured Promissory Note Five [Member]
Receivables with Imputed Interest [Line Items]
Issuance date	Nov. 08, 2022
Principal amount	$ 20,000
Maturity date	Mar. 08, 2023
Interest rate	0.08%
Secured Promissory Note Six [Member]
Receivables with Imputed Interest [Line Items]
Issuance date	Dec. 08, 2022
Principal amount	$ 15,000
Maturity date	Apr. 08, 2023
Interest rate	0.08%
Secured Promissory Note Seven [Member]
Receivables with Imputed Interest [Line Items]
Issuance date	Jan. 05, 2023
Principal amount	$ 27,500
Maturity date	Jul. 05, 2023
Interest rate	0.08%
Secured Promissory Note Eight [Member]
Receivables with Imputed Interest [Line Items]
Issuance date	Jan. 20, 2023
Principal amount	$ 50,000
Maturity date	Jul. 20, 2023
Interest rate	0.08%
Secured Promissory Note Nine [Member]
Receivables with Imputed Interest [Line Items]
Issuance date	Feb. 28, 2023
Principal amount	$ 65,000
Maturity date	Sep. 28, 2023
Interest rate	0.08%

NOTES RECEIVABLE (Details Narra

NOTES RECEIVABLE (Details Narrative)	9 Months Ended
	Sep. 30, 2023 USD ($)
Security Agreement [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Interest and other income	$ 3,373
Loans Receivable [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Proceeds from loan receivables	$ 0

SCHEDULE OF ACCOUNTS PAYABLE AN

SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Accounts payable	$ 439,586	$ 139,603
Credit card	6,801	7,877
Accrued expenses	64,062	82,715
Accrued management fee	16,667	3,183
Total Accounts Payable And Accrued Liabilities	$ 527,116	$ 233,378

SCHEDULE OF STOCK OPTION (Detai

SCHEDULE OF STOCK OPTION (Details) - $ / shares	6 Months Ended	9 Months Ended	12 Months Ended
	Jun. 30, 2023	Sep. 30, 2023	Dec. 31, 2022
Equity [Abstract]
Number of Options, Outstanding, Beginning	854,000,000	854,000,000
Weighted Average Exercise Price, Outstanding, Beginning	$ 0.012	$ 0.012
Weighted Average Remaining life (years), Outstanding		7 years 3 months 25 days	8 years 6 months 21 days
Number of Options, Granted	130,000,000	180,000,000
Weighted Average Exercise Price, Granted		$ 0.012
Weighted Average Remaining life (years), Granted		7 years 3 months 25 days
Number of Options, Exercised
Weighted Average Exercise Price, Exercised
Number of Options, Cancelled/Expired
Weighted Average Exercise Price, Forfeited/canceled
Number of Options, Outstanding, Ending		1,034,000,000	854,000,000
Weighted Average Exercise Price, Outstanding, Ending		$ 0.012	$ 0.012
Number of Options, Exercisable		1,034,000,000
Weighted Average Exercise Price, Exercisable		$ 0.012
Weighted Average Remaining life (years), Exercisable		7 years 3 months 25 days

SCHEDULE OF WARRANTS ACTIVITY (

SCHEDULE OF WARRANTS ACTIVITY (Details) - Warrant [Member] - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of Warrants, Outstanding, Beginning	116,446,154
Weighted Average Exercise Price, Outstanding, Beginning	$ 0.01
Weighted Average Remaining life (years), Outstanding	4 years 6 months 29 days	4 years 4 months 17 days
Number of Options, Granted	599,557,692
Weighted Average Exercise Price, Outstanding, Granted	$ 0.01
Weighted Average Remaining life (years), Outstanding, Granted	5 years
Number of Options, Exercised
Weighted Average Exercise Price, Outstanding, Exercised
Number of Options, Forfeited/canceled
Weighted Average Exercise Price, Outstanding, Forfeited/cancelled
Number of Warrants, Outstanding, Ending	716,003,846	116,446,154
Weighted Average Exercise Price, Outstanding, Ending	$ 0.007	$ 0.01

STOCKHOLDERS_ EQUITY (Details N

STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)					3 Months Ended			6 Months Ended	9 Months Ended
	Apr. 28, 2023	Nov. 09, 2022	Aug. 12, 2022	Aug. 01, 2022	Sep. 30, 2023	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Sep. 30, 2023	Dec. 31, 2022
Subsidiary, Sale of Stock [Line Items]
Sale of common stock issued	125,000,000
Common stock par value					$ 0.001				$ 0.001	$ 0.001
Sale of common stock issued value	$ 800,000
Share price								$ 0.01
Cash					$ 6,504				$ 6,504	$ 226,231
Shares issued					382,250				382,250
Common stock, shares issued					2,831,670,853				2,831,670,853	2,693,190,084
Common stock, shares outstanding					2,831,670,853				2,831,670,853	2,693,190,084
Stock payable										$ 576,000
Restricted common shares									88,615,385
Warrants									$ 559,557,692
Options granted								130,000,000	180,000,000
Investor Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Share price					$ 0.03				$ 0.03
Warrants issued					166				166
Ken Tapp [Member]
Subsidiary, Sale of Stock [Line Items]
Options granted								10,000,000
Aaron Serruya [Member]
Subsidiary, Sale of Stock [Line Items]
Options granted								10,000,000
Kevin Elder [Member]
Subsidiary, Sale of Stock [Line Items]
Options granted								100,000,000
Gordon Kats [Member]
Subsidiary, Sale of Stock [Line Items]
Options granted								10,000,000
Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Number of new shares issued						2,500,000
Consultant Summer Schnog [Member]
Subsidiary, Sale of Stock [Line Items]
Share price					$ 0.01				$ 0.01
Options granted									50,000,000
Private Placement [Member]
Subsidiary, Sale of Stock [Line Items]
Shares issued						2,500,000
Common stock, shares issued					2,831,670,853				2,831,670,853	2,693,190,084
Common stock, shares outstanding					2,831,670,853				2,831,670,853	2,693,190,084
Private Placement [Member] | Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Number of new shares issued							12,500,000
Share price							$ 0.006
Cash							$ 75,000
Private Placement [Member] | Subscription Agreements [Member] | Accredited Investors [Member]
Subsidiary, Sale of Stock [Line Items]
Sale of common stock issued		200,000,000	153,846,154	123,076,923
Common stock par value				$ 0.0065
Warrants exercise price		$ 0.013		$ 0.013
Sale of common stock issued value		$ 1,300,000	$ 1,000,000	$ 800,000
Transfer Agent [Member] | Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Number of new shares issued					0

SCHEDULE OF DILUTED SECURITIES

SCHEDULE OF DILUTED SECURITIES (Details) - shares	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Diluted Securities	1,750,003,846	950,446,154
Warrant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Diluted Securities	716,003,846	112,446,154
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Diluted Securities	1,034,000,000	840,000,000

SCHEDULE OF EARNINGS PER SHARE,

SCHEDULE OF EARNINGS PER SHARE, BASIC AND DILUTED (Details) - USD ($)	3 Months Ended						9 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022
Earnings Per Share [Abstract]
Net income (loss)	$ (371,694)	$ (691,949)	$ (373,727)	$ (573,116)	$ (1,284,362)	$ (1,066,261)	$ (1,437,370)	$ (2,923,738)
(Gain) loss on change in fair value of derivatives
Interest on convertible debt
Net income (loss) - diluted	$ (371,694)			$ (573,116)			$ (1,437,370)	$ (2,923,738)
Weighted average common shares outstanding	2,831,670,853			2,685,608,144			2,805,584,209	2,636,228,346
Effect of dilutive shares
Diluted	2,831,670,853			2,685,608,144			2,805,584,209	2,636,228,346
Basic	$ 0			$ 0			$ 0	$ 0
Diluted	$ 0			$ 0			$ 0	$ 0

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Asset Acquisition [Line Items]
Consulting fees	$ 246,000	$ 307,000
Aquisition Letter Of Intent [Member]
Asset Acquisition [Line Items]
Acquisition of assets	$ 145,000

ACQUISITION (Details Narrative)

ACQUISITION (Details Narrative) - USD ($)				3 Months Ended	9 Months Ended
	Apr. 30, 2023	Apr. 28, 2023	Apr. 12, 2023	Sep. 30, 2023	Sep. 30, 2023	Dec. 31, 2022
Business Acquisition [Line Items]
Controlling interest percentage		100%
Sale of stock consideration received on purchase agreement		$ 1,675,000
Sale of stock consideration received on per transaction		$ 800,000
Sale of stock, number shares issued transaction		125,000,000
Sale of stock, price per share		$ 0.001
Common stock share issued				2,831,670,853	2,831,670,853	2,693,190,084
Attorney and broker fees			$ 180,500
Payment on aquisition				$ 44,229	$ 44,229
Acquisition deposit				440,239	440,239
369 Hemp Inc [Member]
Business Acquisition [Line Items]
Acquisition deposit				385,739	385,739
Meta biogenix USA LLC [Member]
Business Acquisition [Line Items]
Acquisition deposit				$ 54,500	$ 54,500
Warrant [Member]
Business Acquisition [Line Items]
Warrants issued to purchase of common stock			31,250,000
Warrants issued to purchase of common stock			$ 0.01
Board of Directors [Member]
Business Acquisition [Line Items]
Convertible note issued			$ 312,500
Convertible note, discount rate			20%
Convertible note interest rate			6%
Investor [Member]
Business Acquisition [Line Items]
Common stock share issued			31,250,000
Meta biogenix USA LLC [Member]
Business Acquisition [Line Items]
Controlling interest percentage	60%
Sale of stock consideration received on purchase agreement	$ 2,500,000
Sale of stock consideration received on per transaction	$ 400,000
Sale of stock, number shares issued transaction	300,000,000
Sale of stock, price per share	$ 0.001
Sale of stock consideration received	$ 50,000
Warrants issued to purchase of common stock	150,000,000
Minimum [Member]
Business Acquisition [Line Items]
Sale of stock consideration received on per transaction		$ 313,089
Minimum [Member] | Meta biogenix USA LLC [Member]
Business Acquisition [Line Items]
Sale of stock consideration received on per transaction	$ 100,000
Maximum [Member] | Meta biogenix USA LLC [Member]
Business Acquisition [Line Items]
Sale of stock consideration received on per transaction	$ 250,000